

Pharmaceuticals – pollutants of emerging concern in the Baltic Sea region

Dmitry Frank-Kamenetsky

HELCOM, special adviser

M



The Baltic Sea



¥

Unique but fragile ecosystem



Catchment area: 4x area of the sea



Population (catchment): 85 million



Multitude of pressures



HELCOM



The HELCOM vision

"A healthy Baltic Sea environment with diverse biological components functioning in balance, resulting in a good ecological status and supporting a wide range of sustainable economic and social activities."



Baltic Sea Action Plan 2030: structure & goals



mmm





Hazardous substances & litter



Hazardous substances and litter goal

"Baltic Sea unaffected by hazardous substances and litter"



Hazardous substances

- Marine life is healthy;
- Concentrations of hazardous substances are close to natural levels;
- All sea food is safe to eat;
- Minimal risk to humans and the environment from radioactivity.

Marine litter

No harm to marine life from litter.



Hazardous substances

 Minimize input and impact of hazardous substances from human activities.

Marine litter

- Prevent generation of waste and its input to the sea, including microplastics;
- Significantly reduce amounts of litter on shorelines and in the sea.

https://helcom.fi/media/publications/ Baltic-Sea-Action-Plan-2021-update.pdf

Cooperation between HELCOM & PA Hazards of the EU SBSR





http://www.helcom.fi/Lists /Publications/BSEP149.pdf



Compilation of data on the use of pharmaceuticals in veterinary.

<u>Compilation of comprehensive data on pharmaceutical</u> <u>substances in the effluents of WWTP to evaluate input to the</u> <u>fresh water and marine environment.</u>

<u>Compilation of information on pharmaceutical waste</u> <u>management, promotion and advancing of "take back" systems</u> <u>for pharmaceuticals.</u>

Information on active pharmaceutical ingredients (APIs) exceeding the predicted no-effect concentration (PNEC)

Recommendations on improvement of waste management for unused medicines

Report on Micropollutants in WWTPs effluents and policy briefs

Topic: Contaminants of emerging concern



Improve knowledge base on occurrence of pharmaceutical substances in the environment, their persistence and harmful effects and ensure availability of this information for broad expert community by 2025.



Identify priority pharmaceuticals by 2024 utilising the best available knowledge on their releases into the aquatic environment, environmental effects and available data on their use in the region, for efficient risk reduction and for subsequent integration of these substances to HELCOM assessments, as indicators of the state of the Baltic Sea and environmental pressure.



Develop guidance for the environmental monitoring and analysis of pharmaceuticals identified as indicators of the state of the Baltic Sea by 2025.



Organize an information campaign on what not to flush by 2025 (addressing chemicals, pharmaceuticals and litter).



HL27

Strengthen the collection of unused pharmaceuticals from the public in the Baltic Sea region by 2026.

In cooperation with health care institutions, increase awareness and knowledge of consumers about pharmaceuticals containing substances that are persistent and harmful for the environment, when scientifically justified information is available.



Se Helcom

Joint documentation of regional coordination of programmes of measures for the EU MSFD

ACTION 4: Micropollutants in effluents from wastewater treatment plants (PRESSURE WG)

- Step 1: Compilation and assessment of available information and data of micropollutants of concern for Contracting Parties in the Baltic Sea
- Step 2: Compile information from CPs of treatment techniques and experiences-during
- Step 3: Summary report on advanced treatment techniques, including consideration of feasibility, costs, good practice and management options

HELCOM

Micropollutants in effluents of WWTP identified by the HELCOM countries.

- Why call for data?
 - Better understanding of monitoring data
 - Assess need for focused measures in future HELCOM activities
- Long term goal = revise list of Priority substances
- Information request to Contracting Parties -"concern about inputs of various POPs"
- Concern = CPs consider or believe being transported to Baltic Sea Via MWWTPs and RIVERS





Pharmaceutical data coverage

102 WWTPs for two data calls

Data on 117 individual substances were compiled. 11 therapeutic groups:

- anti-inflammatory and analgesic substances,
- antimicrobial and antiparasitic,
- cardiovascular agents,
- central nervous system,
- contrast agents,
- chemotherapeutic agents,
- metabolic and gastrointestinal agents,
- respiratory agents,
- hormones and hormone antagonists,
- recreational drugs,
- metabolites.







Anti-inflammatory and analgesic substances

PLATFORM



(detected 13 out 18 substances)



Hormones and hormone antagonists

(detected 11 out 15 substances)



~~~~~~~



# Policy brief on pharmaceuticals in WWTP.



- Analytical methods, sufficient to detect APIs at concentrations close to respective environmental quality standards, should be applied throughout the region. Detection limits and analysis method should be aligned among countries.
- A database containing information on the occurrence and concentrations of APIs in wastewater, inland surface waters, ground waters and in the marine environment is to be established and made available for expert community. This would help creating a scientifically sound basis for strengthening the management cycle for this group of hazardous substances.
- This database would also serve as the main source of information for the development of respective indicators of the state of the Baltic Sea or advancement of existing ones (e.g. diclofenac).
- Even the limited data compiled in this report proves that active pharmaceutical substances, including those with scientifically proven environmental effect, are continuously released to the aquatic environment.
- Many API from various groups are frequently detected, demonstrating concentrations in effluents at similar level as in influents. In some cases, such as diclofenac and ketoprofen, concentrations in effluents are even higher than in influents. It demonstrates that conventional wastewater treatment is not efficient for removing pharmaceuticals from sewage water.
- Low removal level of APIs from wastewater and limited capacity to restrict their use call for more measures to minimize the release of APIs. These measures should not only be focused on improving technologies at WWTPs to increase their removal efficiency but also target pharmaceuticals at their source (e.g. prescription, consumption reduction, responsible handling and disposal, pretreatment for large hospitals and pharmaceutical manufactories).

mmm

The third holistic assessment of the Baltic Sea environmental health - HOLAS III





## Possibilities towards HOLAS III (2023)







# Thank you.

mmm